Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec
Authors' conclusion
The current results reinforce the safety profile of once-weekly basal insulin icodec and provide guidance on glycaemic management during exercise or fasting in people with T2D treated with icodec.
Study context
- Population
- Basal insulin-treated, physically active adults with T2D (18–75 years, HbA1c ≤ 75 mmol/mol, peak oxygen uptake > 20 mL/kg/min) receiving once-weekly icodec for ≥ 7 weeks
- Participants
- 30 participants
- Comparison
- Exercise week and fasting week vs reference week on once-weekly icodec
- Outcome
- CGM-based time below range < 3.0 mmol/L
Methodological detailssingle-group, reference week, exercise week and fasting week at icodec steady state, blinded continuous glucose monitoring (CGM)
- Single-group
- Reference week, exercise week and fasting week at icodec steady state
- Blinded CGM
Main finding
As reported in the abstract
Further findings
- Intravenous glucose given during fasting
- 50% · 15 events
- Intravenous glucose given during fasting — Earliest after start of fasting
- 10.6 h
Oral carbohydrate given (exercise)
- Pre-exercise
- 1 participant
- During exercise
- 0 participants
- Post-exercise
- 3 participants
Safety
- No clinically significant or severe hypoglycaemia was reported
Original publication
Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec. Diabetes Obes Metab. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →